skip to the content

Efficacy of ACTEMRA/RoACTEMRA in DMARD-refractory RA Patients

Three randomised, double-blind, multicentre Phase III studies have demonstrated the efficacy of ACTEMRA/RoACTEMRA in alleviating the signs and symptoms of RA in patients with an inadequate response to DMARDs (DMARD-IR):

  • OPTION (patients who had an inadequate clinical response to MTX).
  • TOWARD (patients who had an inadequate response to their existing RA therapy, including one or more DMARDs).
  • LITHE (patients who had an inadequate clinical response to MTX; Week 52
    co-primary endpoints of prevention of joint damage and improvement in physical function).